Search Results - mark+yarchoan

2 Results

Sort By:

A DNAJB1-PRKACA fusion kinase peptide vaccine for patients with fibrolamellar hepatocellular carcinoma

Unmet NeedFibrolamellar carcinoma (FLC) is an extremely rare form of cancer. It affects both men and women in approximately 1 in 5,000,000 people with greater frequency among young adults with a median age of diagnosis of 25. Unfortunately, there is no standard of care therapy for this cancer, and patients with this disease have an expected median survival...

Published: 3/14/2025 | Inventor(s): Mark Yarchoan, Elizabeth Jaffee, Aditya Mohan

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Liver Cancer, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities > Immunotherapies

BAFF Synergies with Anti-PD-1 Therapy to Promote Anti-tumor Immunity

Unmet NeedImmune checkpoint therapy has revolutionized how we think about and treat cancers; however, despite remarkable success, immuno-monotherapy has only provided a robust response in ~20-30% of tumors treated. Researchers are now exploring other treatment paradigms including cell, gene, and vaccine therapies to stimulate patents’ immune systems...

Published: 3/13/2025 | Inventor(s): Mark Yarchoan, Elizabeth Jaffee

Keywords(s):

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities